Renal impairment, a frequent complication and poor prognostic factor in relapsed / refractory multiple myeloma ( RRMM ), often leads to poor tolerability of standard regimens.
Researchers have reported outcomes in patients with renal impairment receiving single-agent Belantamab mafodotin ( Blenrep ) ( 2.5 or 3.4 mg/kg; B-cell maturation antigen targeting immunoconjugate not renally metabolized ) from the DREAMM-2 post-hoc analysis.
Eligible patients with relapsed / refractory multiple myeloma had no active renal conditions and adequate renal function ( based on albumin / creatinine ratio [ less than 500 mg/g ] and eGFR [ mL/min/1.73 m2 ]: normal [ greater than or equal to 90 ], mild impairment [ mild, greater than or equal to 60 less than or equal to 90 ], moderate impairment [ moderate, greater than or equal to 30 less than or equal to 60 ] ).
Overall response rates ( 95% CI ) in patients with mild / moderate impairment ( 2.5 mg/kg: 32% [ 21.4–44.0 ]; 3.4 mg/kg: 36% [ 25.6–48.5 ] ) were similar to those in the overall population ( Lancet Oncol 2020 ).
The median duration of response ( DoR ) was not reached ( NR ) in 2.5 mg/kg mild / moderate subgroup ( 95% CI estimate: 4.2 months–NR ); median DoR was 7.5 months ( 4.9–NR ) in 3.4 mg/kg mild / moderate subgroup.
Rates of keratopathy and albuminuria were similar regardless of renal function; rates of anemia, pyrexia, and thrombocytopenia were more frequent in patients with impaired renal function.
eGFR did not change or changed to normal in most patients.
In conclusion, following treatment with single-agent Belantamab mafodotin, patients with mild / moderate renal impairment have achieved a similar efficacy and safety profile as patients with normal renal function. ( Xagena )
Fonte: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020